Evaluation of neo adjuvant chemotherapy response in patients with locally advanced breast cancer
Background: Carcinoma of the breast from the very beginning has been a feared disease. Advanced disease is treated by neoadjuvant chemotherapy (NACT). With this, a study was conducted to evaluate the pathologic response to NACT in locally advanced breast cancer.
Methods: Study was conducted in GSL Medical College, approved by institutional ethics committee, females aged >18 years with locally advanced breast cancer were included in the study. Female <18 years and breast cancer male were not considered. The dimensions are marked and size of the lump compared before and after NACT. Chi-square test was used to find out the significance of study parameters; p<0.05 was considered statistically significant.
Results: Total 110 patients were included in the study, mean age was 50.63±10.76 years and 53% were in pre menopausal women. When pathological response was considered, 12.7% had complete response, 66.4% had partial response and 20.9% had no response to NACT; statistically there was significant difference between pre and post treatment tumor sizes (p<0.05).
Conclusions: Most of the individuals belonged to premenopausal group. Tumour size showed significant decrease after NACT. The overall response rate (complete and partial) after NACT was significant in our study group.
Iqbal J, Kausar B, SaeedAkram M, Zeba A. Survival of women with locally advanced breast cancer at a teaching hospital Lahore. J Pak Med Assoc. 2010;60:721-5.
Buzdar AU. Preoperative chemotherapy treatment of breast cancer. A review cancer. 2007;110:2394-407.
Ali EM, Ahmed RH, Ali AM. Correlation of breast cancer subtypes based on ER, PR and Her2 expression with axillary lymph node status. Cancer Oncol Res. 2014;2(4):51-7.
Onitillo AA, Engel JM, Greenlee RT, Muckesh BN. Breast cancer subtypes based on ER/PR and HER2 expression comparison of clinico pathologic features and survival. Clin Med Res. 2009;7:4-13.
Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res. 1997;396:17.
Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237:474.
Norton JA, Bollinger R, Chang A, Lowry S, Mulvihill SJ, Pass HI, et al. Surgery Basic sciences and Clinical Evidence. Springer; 2001: 1607-1610.
Miglietta. ER, PR, Her2 grading and ki67 before and after neoadjuvant for locally advanced breast cancer. Anticancer Res. 2009;29:1621-6.
Burcombe RJ, Makris A, Richman PI. Evaluation of ER, PR, Her2 and ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147-55.
Singletary SE, Allred C, Bassett LW, et al, Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin N Am. 2003;83:803-19.
Das S. A manual on clinical surgery. 4th ed. Volume 30. Calcutta: 1996: 308-322.
Dondiya HG, Brahmbhatt AP. Neoadjuvant chemotherapy in patients with locally advanced breast cancer. J Cancer Res Therapeutic. 2015;11(3):183-8.
Raina GD, Rath GK, Shukla NK, Mohanti BK, Sharma DW. Clinical and pathological response rates of docetaxel based neoadjuvant chemotherapy in locally advanced breast cancer and comparision with anthracycline based chemotherapy. Indian J Cancer. 2011;48:410-4.